drugset / Trial / NCT01949818

Treatment of Diffuse Large B Cell Lymphoma

NCT01949818

Phase 4 Unknown 120 enrolled Mingzhi Zhang
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.

Timeline

Start
2012-09
Primary completion
2016-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Yangzhengxiaoji capsule Unknown 1.56 g Oral
Background Cyclophosphamide Other / unclassified 750 mg Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Vincristine Small molecule 1.4 g Intravenous